Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Amphotericin liposomal

The caloric contribution from propofol infusions can require adjustment of a patient s nutrition regimen. The caloric contribution from amphotericin liposomal and lipid complex formulations is not clinically relevant. [Pg.685]

Amphotericin-liposomal Abelcet (Elan) Systemic fungal infections... [Pg.274]

Liposomal Amphotericin B This is a highly effective drug against visceral leishmaniasis with remarkably few side effects. There is, however, only one producer and the price per treatment (US 1,500) is beyond the reaches for most communities affected by the disease. [Pg.178]

Prolonged presence of the drug at the site of injection is the aim of liposome encapsulation of drugs, which are injected in the vitreous body. Both amphotericin and gentamicin in liposome formulations were cleared from the injection site significantly more slowly than the free drug residence times depended on liposome size and, in some cases, on bilayer composition (Tremblay et al., 1985 Barza et al., 1985, 1987 Fishman et al., 1986). [Pg.309]

Ahrens, J., Graybill, J., Craven, P., and Taylor, R. (1984). Treatment of experimental murine candidiasis with liposome-associated amphotericin B, Sabouraudia, 22, 263-265. [Pg.316]

J. (1985). Ocular toxicity of intravitreally injected liposomal amphotericin B in rhesus monkeys. Am. J. Ophthalmol., 100, 259-263. [Pg.317]

Lopez-Berestein, G., Metha, R., Hopfer, R. L., Mills, K., Kasi, L., Metha, K., Fainstein, V., Luna, M., Hersh, E. M., and Juliano, R. L. (1983). Treatment and prophylaxis of disseminated infection due to Candida albicans in mice with liposome-encapsulated amphotericin B, J. Infect. Pis.. 147, 939-945. [Pg.326]

Altered tissue distribution of amphotericin B by liposomal encapsulation Comparison of normal mice and mice infected with Candida albicans. Cancer Drug Deliv., 1, 199-205. [Pg.327]

E. M., and Juliano, R. L. (1984c). Liposome-encapsulated amphotericin B for treatment of disseminated candidiasis in neutropenic mice, J. Infect. Pis., 150, 278-283. [Pg.327]

P. (1985). Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer A preliminary study, J. Infect. Pis., 151, 704-710. [Pg.327]

Lopez-Berestein, G. (1988). Liposomal amphotericin B in antimicrobial therapy, in Liposomes as Drug Carriers Recent Trends and Progress (G. Gregoriadis, ed.), John Wiley and Sons, Chichester, pp, 345-352. [Pg.327]

Lopez-Berestein, G. (1989). Treatment of systemic fungal infections with liposomal-amphotericin B, in Liposomes in the Therapy of Infectious Diseases and Cancer (G. Lopez-Berestein and I. J. Fidler, eds.), Alan R. Liss, New York, pp. 317-327. [Pg.327]

Pilot study of amphotericin B entrapped in sonicated liposomes in cancer patients with fungal infections, Eur. J. Cancer cun. Oncol., 24, 527-538. [Pg.334]

Tremblay, C., Barza, M., Flore, C., and Szoka, F. (1984). Efficacy of liposome-intercalated Amphotericin B in the treatment of systemic candidiasis in mice, Antimicrob. Ag. Chemother.. [Pg.336]

Wiebe, V. J., and Degregorio, M. W. (1988). Liposome-encapsulated amphotericin B A promising new treatment for disseminated fungal infections. Rev. Infect. Pis., 10. 1097-1101. [Pg.338]

Amphotericin B-induced ARF occurs in as many as 40% to 65% of patients treated with the conventional desoxycholate formulation.30 Nephrotoxicity is due to renal arterial vasoconstriction and distal renal tubule cell damage. Risk factors include high doses, treatment for at least 7 days, preexisting kidney dysfunction, and concomitant use of other nephrotoxic drugs.31 Three lipid-based formulations of amphotericin B have been developed in an attempt to decrease the incidence of ARF amphotericin B lipid complex, amphotericin colloidal dispersion, and liposomal amphotericin B. The range of... [Pg.369]

Treatment fluconazole, itraconazole, ketoconazole, Amphotericin B Consider liposomal products decrease or stop CSA or TAC to minimize nephrotoxicity Remember to adjust doses of renally eliminated drugs (e.g., acyclovir, ganciclovir, TMP-SMX)... [Pg.847]

In patients who have failed initial therapy (i.e., salvage), liposomal amphotericin products, itraconazole, or the echinocandin caspofungin can be used. Itraconazole has a response rate of approximately 40%.100 Oral itraconazole exhibits erratic absorption the IV formulation is suspended in cyclodextrin, which is eliminated renally, and thus IV itraconazole should be avoided in patients with a creatinine clearance of less than 30 mL/minute (0.29 mL/s m2).103 Itraconazole also has negative inotropic cardiac effects and increases the serum concentrations of medications (e.g., cyclophosphamide, etopo-side, calcineurin inhibitors, and sirolimus). [Pg.1462]

Liposomal amphotericin B 3 mg/kg IV daily Lower incidence of nephrotoxicity and infusion reactions more expensive. [Pg.1473]

ABLC = Amphotericin B Lipid Complex ABCD = Amphotericin B Colloidal Dispersion L-AMB = Liposomal Amphotericin B... [Pg.147]

Liposomal amphotericin B (AmBisome) may be more appropriate for disseminated disease. [Pg.427]

Lipid-associated formulations of amphotericin B, liposomal amphotericin B (AmBisome) and amphotericin B lipid complex (Abelcet) have been approved for use in proven cases of candidiasis however, patients with invasive candidiasis have also been treated successfully with amphotericin B colloid dispersion (Amphotec or Amphocil). The lipid-associated formulations are less toxic but as effective as amphotericin B deoxycholate. [Pg.435]

Solid-organ transplantation Liver transplantation Micafungin 50 mg (1 mg/kg in patients under 50 kg) IV daily Patients with two or more key risk factor Amphotericin B IV 10-20 mg daily or Liposomal amphotericin B (AmBisome) 1 mg/kg/day or flucona-... [Pg.436]

Candida albicans, C. tropicalis, C parapsilosis and resolution of signs and symptoms of infection Remove existing central venous catheters when feasible, plus Amphotericin B IV 0.6 mg/k day or Fluconazole IV/po 6 mg/kg/day or An echinocandin or Amphotericin B IV 0.7 mg/kg/day plus fluconazole IV/po 800 mg/day Patients intolerant or refractory to other therapf Amphotericin B lipid complex IV 5 m k day Liposomal amphotericin B IV 3-5 mg/kg/day Amphotericin B colloid dispersion IV 2-6 mg/k day (continued)... [Pg.436]

Amphotericin B nephrotoxicity can be reduced by slowing the infusion rate to 24 hours or, in at-risk patients, substituting liposomal amphotericin B. [Pg.867]

Jullien S, Vertut-Croquin A, Bratjburg J, Bolard J. Circular dichroism for the determination of amphotericin B binding to liposomes. Anal Biochem 1988 172 197. [Pg.109]

Janoff AS, et al. Amphotericin B lipid complex (ABLC ) a molecular rationale for the attenuation of AmB related toxicities. J Liposome Res 1993 3 451. [Pg.110]

Paul M, et al. Activity of a new liposomal formulation of amphotericin B against two strains of Leishmania infantum in a murine model. Antimicrob Agents Chemother 1997 41 1731. [Pg.110]

Inselmann G, Volkmann A, Heidemann H. Comparison of the effects of liposomal amphotericin B and conventional amphotericin B on propafenone metabolism and cytochrome P450 in rats. Antimicrob Agents Chemother 2000 44 131. [Pg.110]


See other pages where Amphotericin liposomal is mentioned: [Pg.1115]    [Pg.1115]    [Pg.109]    [Pg.285]    [Pg.321]    [Pg.336]    [Pg.179]    [Pg.370]    [Pg.1217]    [Pg.1221]    [Pg.1221]    [Pg.1462]    [Pg.1473]    [Pg.556]    [Pg.74]    [Pg.436]    [Pg.36]    [Pg.109]   
See also in sourсe #XX -- [ Pg.17 , Pg.319 ]




SEARCH



Amphotericin

Amphotericin B liposomal

Amphotericin B liposomal AmBisome)

Amphotericin liposomal encapsulation

Amphotericin liposomal formulation

Amphotericin, liposomal nephrotoxicity

Fungal infections, invasive liposomal amphotericin

Liposomal amphotericin L-AmB)

© 2024 chempedia.info